Renal Cell Carcinoma | Treatment Sequencing | US | 2019

KEY BENEFITS AND USES

Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
Identify untapped treatment scenarios and key competitors to aid trial design.
Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

• Where is my product positioned vs. competitors in the treatment journey?

• What are physicians’ most frequent treatment sequences—who is

benefiting and how can I defend my assets share and position?

• What are the market-relevant treatment scenarios according to oncology

experts?

• Where are the untapped business opportunities that I can capitalize

upon?

• How can I optimize trial design and ensure a competitive edge for my

pipeline asset?

GEOGRAPHIES

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. physicians

2019 COVERAGE

Colorectal Cancer (US)

Multiple Myeloma (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)

Non-Small-Cell Lung Cancer (US)

Ovarian Cancer (US)

Prostate Cancer (US)

Renal Cell Carcinoma (US)

KEY FEATURES

Market-relevant treatment scenarios and subpopulations from oncology experts
Drug share and treatment rates mapped to treatment journey using physician survey data
Physicians’ most frequently selected treatment sequences
Access to expert oncology analysts for bespoke support

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment

patterns in market-relevant treatment scenarios and drug share mapped to

treatment journey. The quantitative sequencing analysis illuminates drug

positioning through primary market research-based insights from physicians

and DRG oncology experts’ assumptions.

Contact us